KalVista Pharmaceuticals Reports First Fiscal Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
KalVista Pharmaceuticals (KALV) Tops Q3 EPS by 10c
September 8, 2022 7:05 AM EDTKalVista Pharmaceuticals (NASDAQ: KALV) reported Q3 EPS of ($0.94), $0.10 better than the analyst estimate of ($1.04).
Cash Position: Cash, cash equivalents and marketable securities were $142.1 million as of July 31, 2022, compared to $166.2 million as of April 30, 2022. The decrease in the net cash and marketable securities... More
